{"entity":{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","aka":[],"tldr":"The ADC-immunotherapy pair that doubled survival in advanced disease now also works around surgery, in fit and unfit patients alike.","summary":"Enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, combined with pembrolizumab is the first regimen to displace platinum chemotherapy at every stage of a common solid tumour, bladder and urothelial cancer. Nectin-4 is expressed on almost all urothelial cancers, and the MMAE payload induces immunogenic cell death and dendritic-cell maturation that the PD-1 antibody then exploits. Three positive phase 3 trials underpin it: EV-302 / KEYNOTE-A39 in metastatic disease, where survival improved substantially over chemotherapy, EV-303 / KEYNOTE-905 in cisplatin-ineligible muscle-invasive disease, approved in November 2025, and EV-304 / KEYNOTE-B15 in cisplatin-eligible disease, positive in December 2025. The pairing now serves fit and unfit patients alike.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04223856: EV-302 / KEYNOTE-A39","url":"https://clinicaltrials.gov/study/NCT04223856"},{"label":"ClinicalTrials.gov NCT03924895: EV-303 / KEYNOTE-905","url":"https://clinicaltrials.gov/study/NCT03924895"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ev-302","ev-303","ev-304"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"enfortumab-vedotin","b":"pembrolizumab","rationale":"Nectin-4 is near-universal in urothelial cancer; MMAE induces immunogenic cell death and dendritic-cell maturation that pembrolizumab exploits.","evidence":"Three positive phase 3 trials.","pairingType":"combination"},"route":"/pairings/ev-pembro-continuum/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/"},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/"},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/"}]}}